Cargando…

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Detalles Bibliográficos
Autores principales:	Brandão, Mariana, Reyal, Fabien, Hamy, Anne-Sophie, Piccart-Gebhart, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555612/ https://www.ncbi.nlm.nih.gov/pubmed/31231570 http://dx.doi.org/10.1136/esmoopen-2019-000515

Ejemplares similares

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
por: Grandal, Beatriz, et al.
Publicado: (2021)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Ethical Obligation Towards Research Subjects
Publicado: (2007)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach
por: Laas, Enora, et al.
Publicado: (2019)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Informed Consent: An Ethical Obligation or Legal Compulsion?
por: Satyanarayana Rao, K H
Publicado: (2008)

Physicians’ Attitudes and Ethical Obligations to Pharmacogenetic Testing
por: Muflih, Suhaib, et al.
Publicado: (2020)

Broad Medical Uncertainty and the ethical obligation for openness
por: Brown, Rebecca C. H., et al.
Publicado: (2022)

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
por: Laas, Enora, et al.
Publicado: (2021)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Practising the ethics of person‐centred care balancing ethical conviction and moral obligations
por: Ekman, Inger
Publicado: (2022)

Cancer drugs, survival and ethics: a critical look from the inside
por: Piccart, Martine, et al.
Publicado: (2017)

Early Referral in Brachial Plexus Injury: An Ethical Obligation
por: Morris, Bryn E., et al.
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Interactive exploration of a global clinical network from a large breast cancer cohort
por: Sella, Nadir, et al.
Publicado: (2022)

Do physicians have an ethical obligation to care for patients with AIDS?
por: Angoff, N. R.
Publicado: (1991)

Reporting Results of Research Involving Human Subjects: An Ethical Obligation
por: Alley, Allison Baer, et al.
Publicado: (2015)

Influences of (in)congruences in psychological entitlement and felt obligation on ethical behavior
por: Chen, Qin, et al.
Publicado: (2023)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Genome of the ramshorn snail Biomphalaria straminea—an obligate intermediate host of schistosomiasis
por: Nong, Wenyan, et al.
Publicado: (2022)

Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data
por: Abécassis, Judith, et al.
Publicado: (2019)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Mandating COVID-19 Vaccine for Nursing Home Staff: An Ethical Obligation
por: Dumyati, Ghinwa, et al.
Publicado: (2021)

Ethical obligations for supporting healthcare workers during the COVID-19 pandemic
por: Supady, Alexander, et al.
Publicado: (2021)

Ethical issues and obligations with undocumented immigrants relying on emergency departments for dialysis
por: Kluesner, Nicholas H., et al.
Publicado: (2021)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kn6mre6ts04apnn432dhcmi5md